KMTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kestra Medical Technologies Ltd (KMTS) does not currently present a strong buy opportunity for a beginner, long-term investor with $50,000-$100,000 available. While the company has shown strong revenue growth and improving financial metrics, the lack of significant positive trading signals, neutral sentiment from hedge funds and insiders, and no recent news catalysts suggest waiting for a clearer entry point.
The MACD is positive and contracting, indicating a potential slowing of upward momentum. RSI is neutral at 62.724, and moving averages are converging, showing no clear trend. The stock is trading near its pivot point of 21.047, with resistance at 23.79 and support at 18.304.
Revenue increased significantly by 53.40% YoY in Q2 2026, and gross margin improved by 27.76% YoY, indicating operational efficiency. Analyst maintains a Buy rating despite lowering the price target slightly.
Net income remains negative at -$32.785M, and EPS is still in the red at -0.64, despite improvements. No recent news or significant trading trends from hedge funds or insiders. Congress trading data is also absent.
In Q2 2026, revenue increased by 53.40% YoY to $22.565M. Net income improved by 38.39% YoY but remains negative at -$32.785M. EPS improved by 33.33% YoY to -0.64, and gross margin increased to 50.63%, up 27.76% YoY.
BTIG lowered the price target from $32 to $30 but maintained a Buy rating. The adjustment reflects updates to models based on CMS's proposed rule for FY27 inpatient prospective payment system.
